Walvax沃森生物

CN
EN

Products List

Walvax has successfully developed 9 licensed vaccines, including SARS-CoV-2 mRNA Vaccine, 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV2).

 

Walvax proactively promotes PQ application of its products, and is proceeding with PQ application of multiple products. In 3 to 5 years, Walvax's WHO-PQ will yield fruitful results, which brings its internationalization to a higher level.

Quick Links

Pipeline
SARS-CoV-2 mRNA Vaccine

For active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)

For the prevention of cervical cancers and precancerous lesions caused by human papillomavirus types 16/18.

Haemophilus Influenzae Type b Conjugate Vaccine

Prevention of invasive infections caused by Haemophilus Influenzae type b for infants and children 2 months through 5 years of age.

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed

Prevention of pertussis, diphtheria and tetanus for infants and children 3 months through 6 years of age.